2-PMAP vs beta-amyloid

Is there prevention of Alzheimer's disease?

Weekly Pharmacy www.apteka.ua based on the materials of New York University Langone Medical Center:
New Amyloid-Reducing Compound Could Be a Preventive Measure Against Alzheimer’sAccording to the results of a study by scientists from the New York University Medical Center (USA), a compound, 2-([pyridine-2-ylmethyl]-amino)-phenol (2-PMAP), has been identified, which contributes to a decrease in the level of amyloid proteins in the brain by more than 2 times, which are associated with Alzheimer's disease.

The results of the study are published in the journal Annals of Neurology (Asuni et al., Modulation of amyloid precursor protein expression reduces b-amyloid deposition in a mouse model).

In an animal experiment, scientists found that the compound 2-PMAP reduces the production of amyloid precursor proteins. These proteins are usually fermentable in such a way that one of the fragments after fermentation turns out to be beta-amyloid. Thus, scientists have determined that 2-PMAP, even in low concentrations, significantly reduces the production of amyloid proteins, while reducing the level of beta-amyloid by 50% or more. After 4 months of taking 2-PMAP by animals, the level of amyloid deposits and cognitive deficits sharply decreased.

At the moment, scientists are working on a chemical modification of this compound in order to increase its effectiveness. However, the compound 2-PMAP seems to have advantages over other compounds that reduce beta-amyloid levels. One of them is the effective overcoming of the blood–brain barrier.

The target for the prevention of Alzheimer's disease is beta-amyloid. Decades before the development of dementia symptoms, this protein begins to accumulate in the form of clots in the brain. Reducing the production of beta-amyloid in adulthood and, thus, reducing part of the load on the brain is a good strategy for the prevention of Alzheimer's disease.

Studies conducted about 2 years ago showed that something like this happens naturally in 0.5% of Icelanders due to a mutation noted in them. Thus, the production of beta-amyloid throughout life in these people is reduced by almost half, which slows down the process of their cognitive impairment in the elderly and increases their life expectancy. Also, such people have almost no cases of Alzheimer's disease.

The researchers hope that the results of this study will help develop a preventive treatment for such neurodegenerative diseases, while it should be safe enough to follow it daily for many years.

Portal "Eternal youth" http://vechnayamolodost.ru06.06.2014